Martha J. Demski - 06 Mar 2023 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Reporting relationship: Director
Issuer ticker: ADMA
Reported as of: 06 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Mar 2023, 20:30:36 UTC
Prior SEC filing: 24 Jun 2022
Next SEC filing: 11 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Martha J. Demski, by Brian Lenz as Attorney-in-fact

Key filing fact

Martha J. Demski filed Form 4 for ADMA BIOLOGICS, INC. (ADMA) on 08 Mar 2023.

Key facts

This page summarizes Martha J. Demski's Form 4 filing for ADMA BIOLOGICS, INC. (ADMA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Mar 2023, 20:30.

Change

Previous filing in this sequence was filed on 24 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADMA transaction

Common Stock

Award

Transaction value: $0
Shares: +25,815
Change %: +84%
Price: $0.000000
Shares after: 56,601
Date: 06 Mar 2023
Ownership: See Footnote
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADMA transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +51,630
Change %
Price: $0.000000
Shares after: 51,630
Date: 06 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 51,630
Exercise price: $3.35
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.

Footnote F2

Includes, as of the transaction date, (i) 25,815 RSUs granted on March 6, 2023 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 13,293 RSUs granted on March 7, 2022, which will vest in full on March 7, 2023; and (iii) 17,493 shares of common stock owned by the reporting person.

Footnote F3

These shares are held in the trust account of the Martha J. Demski Trust U/D/T 10/01/94, for which the reporting person serves as trustee.

Footnote F4

The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.